Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Unknown 1Not yet recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 16Melanoma 8Lung Neoplasms 8Neoplasm Metastasis 6Colorectal Neoplasms 6Solid Tumours 5Neoplasms 5Breast Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Colonic Neoplasms 3Thyroid Cancer, Papillary 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neurofibrosarcoma 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × AZD 6244 × Clear all
NCT01222689 2020-07-31

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01658943 2016-03-09

S1115

National Cancer Institute (NCI)

Phase 2 Completed
137 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00372944 2014-08-13

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

AstraZeneca

Phase 2 Completed
70 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡